Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Sep;35(9):e23934.
doi: 10.1002/jcla.23934. Epub 2021 Jul 31.

CircRNAs as promising biomarker in diagnosis of breast cancer: An updated meta-analysis

Mingyu Chu  1 , Yaqun Fang  1 , Yucui Jin  1   2
Affiliations
Meta-Analysis

CircRNAs as promising biomarker in diagnosis of breast cancer: An updated meta-analysis

Mingyu Chu et al. J Clin Lab Anal. 2021 Sep.

Abstract

Background: Circular RNAs (circRNAs) have been identified to be involved in onset and progression of multiple malignant tumors. The present study aimed to systematically evaluate the diagnostic values of circRNAs in breast cancer.

Methods: The PubMed, Web of Science, Embase, CNKI, and Wanfang online databases were searched for the relevant studies before December 31, 2020. Statistical analysis of the diagnostic tests was performed based on STATA 16.0, Meta-DiSc 1.4, and RevMan 5.3 software. The threshold effect and publication bias were measured by the Spearman correlation and Deeks' funnel plot asymmetry test, respectively.

Results: Twenty-one studies from 13 articles were included in this meta-analysis. The pooled sensitivity and specificity were 0.77 and 0.71, respectively. The pooled positive likelihood ratio (PLR), negative likelihood ratio (NLR), and overall diagnostic odds ratio (DOR) were 2.6, 0.33, and 8, respectively. Furthermore, the area under the summary receiver operator characteristic curve was 0.80. In addition, down-regulated circRNAs achieved a diagnostic performance higher than up-regulated circRNAs, with area under curve (AUC) values of 0.81 and 0.74, respectively. Studies based on tissue samples presented better diagnostic accuracy than those based on plasma samples, with AUC values of 0.80 and 0.67. In addition, two circRNAs, including circ_0001073 and circTADA2A-E5/E6, showed higher diagnostic values, with AUC value of 0.990 and 0.937, respectively. According to the results of meta-regression, the case size (p<0.05) might be the source of the heterogeneity.

Conclusion: CircRNAs exhibited a high diagnostic value for breast cancer and may function as potential diagnostic biomarkers for breast cancer.

Keywords: biomarker; breast cancer; circular RNA; diagnosis; meta-analysis.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

FIGURE 1
FIGURE 1
Steps for screening eligible articles
FIGURE 2
FIGURE 2
Quality assessment of eligible studies. “Low” means “at low risk of bias” or having “low concern regarding applicability”; “High” means “at risk of bias” or having “concerns regarding applicability”; and “unclear” means insufficient data for judgment
FIGURE 3
FIGURE 3
Forest plots of sensitivity and specificity of circRNAs in the diagnosis of breast cancer. (A) Pooled sensitivity for circRNAs. (B) Pooled specificity for circRNAs
FIGURE 4
FIGURE 4
The summary receiver operator characteristic (SROC) curve of circRNAs in the diagnosis of breast cancer. The study case numbers inside of the graphics represent the corresponding articles we used for the meta‐analysis, which can refer to Table 1
FIGURE 5
FIGURE 5
Sensitivity analysis to assess the stability results. Sensitivity analysis was performed by omitting each study one by one, and the omitted studies were shown on the left side of the graphics
FIGURE 6
FIGURE 6
The Deeks’ funnel plot asymmetry test for publication bias. Each point represents a separate study for the indicated association. The study case numbers inside of the graphics represent the corresponding articles we used for meta‐analysis, which can refer to Table 1
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209‐249. - PubMed
    1. Migowski A. Early detection of breast cancer and the interpretation of results of survival studies. Ciencia & Saude Coletiva. 2015;20(4):1309. - PubMed
    1. Coleman C. Early detection and screening for breast cancer. Semin Oncol Nurs. 2017;33(2):141‐155. - PubMed
    1. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast‐cancer incidence. The New England Journal of Medicine. 2012;367(21):1998‐2005. - PubMed
    1. Drukteinis JS, Mooney BP, Flowers CI, et al. Beyond mammography: new frontiers in breast cancer screening. The American Journal of Medicine. 2013;126(6):472‐479. - PMC - PubMed

Publication types